Novo Nordisk and Anthropic have formed a collaboration to deploy Claude in drug discovery and software development, marking the pharmaceutical company's latest move to embed AI across its research operations. The deal gives Novo Nordisk's scientists and computational teams access to Anthropic's frontier models to build targeted tools for scientific workflows and biological reasoning.
What the partnership covers
The companies will jointly identify drug-discovery bottlenecks and develop AI applications to address them. Novo Nordisk plans to test Claude Science in select R&D workflows, focusing on problems where their combined expertise is expected to deliver the greatest impact.
Beyond the lab, the pharmaceutical company will use Anthropic's models for AI-assisted software development as it works to expand AI use across its operations. The collaboration includes data-governance controls and human oversight to keep the technology aligned with Novo Nordisk's ethical and compliance standards.
Leadership perspectives
"This partnership is another testament to our ambition to become the world's most AI-driven healthcare company, building on Novo's current AI initiatives with other technology partners," said Mike Doustdar, president and CEO of Novo Nordisk. "Joining forces with Anthropic will supercharge our R&D organization and help us on our mission to bring new, transformative health solutions to people living with chronic diseases."
Dario Amodei, cofounder and CEO of Anthropic, framed the collaboration around compressed timelines. "AI's increasing capability brings with it the potential to compress a century's worth of biological and medical breakthroughs into a decade," he said. "By giving leading researchers access to safe, capable and trusted frontier models, we can shorten research timelines, improve outcomes and discover medicines and treatments that significantly improve human life."
A pattern of AI investments
The Anthropic deal extends a series of AI partnerships Novo Nordisk has assembled this year. In April, the company partnered with OpenAI to apply its models across drug discovery, manufacturing, commercial operations, and supply-chain management. Doustdar described that agreement as "one important step in positioning Novo Nordisk to lead in the next era of healthcare."
August brought a partnership with H1 to develop AI models for clinical trial design, enrollment, and site selection. Novo Nordisk also expanded its relationship with Amazon Web Services to establish an AI drug-discovery hub in London, where it will use AWS tools to analyze genomic, imaging, and clinical data and automate research workflows.
Why this matters for science and research professionals
For researchers and computational scientists in drug development, this string of partnerships signals a shift in how large pharmaceutical companies are procuring AI capabilities. Rather than building everything in-house, Novo Nordisk is layering multiple frontier models into specific scientific workflows. The pattern suggests that domain expertise in biology and chemistry remains the hard requirement - AI fluency is becoming the expected complement. Teams that can translate a research bottleneck into a well-scoped AI problem will be positioned to move faster than those waiting for a single platform to solve everything.
Your membership also unlocks:
